Loading data for ARTL — first visit, this takes a few seconds.
Artelo Biosciences, Inc. (ARTL)
NasdaqCM: ARTL
· 即時價格 · USD
6.36
+0.40 (6.71%)
收盤價： Sep 01, 2026, 2:52 PM
股價、關鍵數字和最新消息，都在這一頁。
Artelo Biosciences, Inc.（ARTL）股價、分析與資料
無可用資料
| 買價 | 4.68 |
| 市值 | 3.43M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -12.7M |
| -0.07 | |
| -101.07 | |
| n/a | |
| -7.12 | |
| P/B (ttm) | 5.26 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 6.94 |
| 成交量 | 586,565 |
| 20 日平均成交量 | 38,926 |
| 開盤價 | 6.06 |
| 前收盤價 | 5.96 |
| 當日區間 | 5.34 - 6.79 |
| 52 週範圍 | 4.68 - 249.75 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpy...
完整的公司簡介財報驚奇
Artelo Biosciences 已於 Feb 24, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.12 超出預期 4.59, 年增 99.43% 成長.
